John Newman Analyst Performance

John Newman is a stock analyst at Canaccord Genuity Group focused in the medical sector, covering 47 publicly traded companies. Over the past year, John Newman has issued 12 stock ratings, including buy and hold recommendations. While full access to John Newman's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights John Newman's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Analyst Ranking

Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat

Average Return

00.00% 12-Month ROI

Success Rate

00.00% Profitable Ratings

Total Ratings

395 Last 11 Years

Buy Recommendations

90.61% 357 Buy Ratings

Companies Covered

47 Unique Companies

Ratings Distribution

Rating	Percentage	Count
Strong Buy	0.0%	0 ratings
Buy	90.6%	357 ratings
Hold	9.4%	37 ratings
Sell	0.0%	0 ratings

Out of 394 total stock ratings issued by John Newman at Canaccord Genuity Group, the majority (90.6%) have been Buy recommendations, followed by 9.4% Hold.

Best & Worst Calls

• Best Call

  0000.0%

  DMTX

  Jun 2017

  Subscribe to MarketBeat All Access to get analyst recommendation ROI.
• Worst Call

  000.0%

  VSAR

  Sep 2017

  Subscribe to MarketBeat All Access to get analyst recommendation ROI.

Exchange Coverage

Exchange	Percentage	Count
NASDAQ	89.4% of companies on NASDAQ	42 companies
NYSE	8.5% of companies on NYSE	4 companies
PINK	2.1% of companies on PINK	1 company

John Newman, an analyst at Canaccord Genuity Group, currently covers 47 companies listed on NASDAQ, NYSE and PINK, with the majority traded on NASDAQ.

Coverage Focus

Sector Icon	Sector	Percentage
	Medical 41 companies	87.2%
	Miscellaneous 4 companies	8.5%
	Finance 1 company	2.1%
	Business Services 1 company	2.1%

John Newman of Canaccord Genuity Group specializes in stock coverage within the Medical sector, with additional focus on and Finance companies.

Coverage Industries

Industry	Percentage
MED - BIOMED/GENE 16 companies	34.0%
PHARMACEUTICAL PREPARATIONS 13 companies	27.7%
MED - DRUGS 4 companies	8.5%
BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC 4 companies	8.5%
Miscellaneous 4 companies	8.5%
BIOTECHNOLOGY 2 companies	4.3%
MED INSTRUMENTS 1 company	2.1%
FIRE, MARINE, & CASUALTY INSURANCE 1 company	2.1%
GOVERNMENT SERVICES 1 company	2.1%
MED - GENERIC DRG 1 company	2.1%

John Newman's Ratings History at Canaccord Genuity Group

Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe

Start Date

End Date

All Ratings Strong Buy Buy Hold Sell Rating

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription

12-Month ROIUpgrade to All Access to use the All ROI Filter

Export to Excel

Company	Report Date	Action	Report Date Price	12-Month Price Target	Rating	12-Month Price & ROI	Details
REGN Regeneron Pharmaceuticals	10/23/2025	Reiterated Rating	$584.74	$850.00	Buy	$0.00 00.00% ROI
DCTH Delcath Systems	10/21/2025	Reiterated Rating	$11.51	$21.00	Buy	$0.00 00.00% ROI
REGN Regeneron Pharmaceuticals	10/14/2025	Reiterated Rating	$562.31	$850.00	Buy	$0.00 00.00% ROI
MRUS Merus	9/29/2025	Downgrade	$93.56	$97.00	Hold	$0.00 00.00% ROI
MCRB Seres Therapeutics	9/24/2025	Boost Price Target	$17.56	$22.00	Buy	$0.00 00.00% ROI
REGN Regeneron Pharmaceuticals	7/23/2025	Reiterated Rating	$572.92	$850.00	Buy	$0.00 00.00% ROI
ALLO Allogene Therapeutics	3/14/2025	Reiterated Rating	$1.90	$14.00	Buy	$0.00 00.00% ROI
ATRA Atara Biotherapeutics	3/11/2025	Reiterated Rating	$6.16	$17.00	Buy	$0.00 00.00% ROI
BNTX BioNTech	3/11/2025	Reiterated Rating	$103.54	$171.44	Buy	$0.00 00.00% ROI
MRKR Marker Therapeutics	3/5/2025	Initiated Coverage	$1.38	$8.00	Buy	$0.00 00.00% ROI
CADL Candel Therapeutics	2/19/2025	Initiated Coverage	$9.52	$20.00	Buy	$0.00 00.00% ROI
ATRA Atara Biotherapeutics	1/17/2025	Lower Price Target	$6.88	$17.00	Buy	$0.00 00.00% ROI

Stock Forecasts and Research Tools

Sign in to your free account to enjoy these benefits

• In-depth profiles and analysis for 20,000 public companies.
• Real-time analyst ratings, insider transactions, earnings data, and more.
• Our daily ratings and market update email newsletter.

Sign in to your free account to enjoy all that MarketBeat has to offer.

• Sign In
• Create Account

Your Email Address:

Email Address Required

Your Password:

Password Required

Log In

---

or

Sign in with Facebook Sign in with Google

Forgot your password?

Your Email Address:

Please enter your email address.

Please enter a valid email address

Choose a Password:

Please enter your password.

Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character.

Create My Account (Free)

---

or

Sign in with Facebook Sign in with Google

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.